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1. Introduction
   Lucifensin is one of the well-characterised antibacterial 
substance from maggots of Lucilia sericata (L. sericata) 
involved in maggot therapy[1]. It is assumed that it plays 
a role in the inhibition of some wound pathogens since 
it has been found in excretion/secretion of maggots. 
Lucifensin was originally isolated from larval guts and was 
subsequently detected in salivary glands, the fat body and 
haemolymph[1]. Using in situ hybridisation, expression of 
lucifensin has been confirmed in the salivary glands of 
all larval stages. Expression has been also occasionally 
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Objective: To investigate the antibacterial properties of lucifensin in maggots of Lucilia sericata 
after septic injury.  
Methods: In our preliminary study we have shown that injuring the maggots with a needle 
soaked in lipopolysaccharide solution induced within 24 h lucifensin expression in the fat body 
and in the grease coupler of the salivary glands. It is assumed that lucifensin is secreted solely 
from this tissue into the haemolymph (similar to other insect defensins) and not into secreted/
excreted products. We used high‐performance liquid chromatography fractionation and radial 
diffusion assay to investigate the antibacterial properties of haemolymph extracted from larvae 
after septic injury.
Results: After septic injury, production of lucifensin in the haemolymph is increased. This led to 
higher antibacterial activity of such haemolymph in comparison to non-stimulated larvae. 
Coclusions: These results suggest that beside the previously demonstrated role of lucifensin 
in the debridement therapy, lucifensin is simultaneously important as a part of the systematic 
immune response.
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This is a valuable research work in 
which authors have demonstrated that 
the antimicrobial peptide lucifensin 
was not found in the digestive tract 
of the larvae of the fly L. sericata as 
was believed and that lucifesin was 
isolated to the haemolymph and found 
higher antibacterial activity of such 
haemolymph in comparison to non-
stimulated larvae.
Details on Page 361
Article history:
Received 21 Feb 2014
Received in revised form 1 Mar, 2nd revised form 6 Mar, 3rd revised form 11 Mar 2014
Accepted 21 Mar 2014
Available online 28 May 2014
Ivana Valachova et al./Asian Pac J Trop Biomed 2014; 4(5): 358-361 359
detected in a few cells of the fat body and in the grease 
coupler of salivary glands. Surprisingly, no expression of 
lucifensin has been detected in the gut although lucifensin 
was originally purified from this tissue. This could 
mean that, after secretion from salivary glands into the 
environment, lucifensin is ingested by maggots along with 
food and passes through the digestive tract[2].
   The antibacterial activity often results in a constitutive 
expression of antibacterial factors (produced at a constant 
level) or in an inductive expression of antibacterial factors 
upon bacterial stimulation[3]. It has previously been 
described that the larval immune system might be activated 
to induce production of antibacterial substances to survive 
in an infectious environment[4,5]. Synthesis of antimicrobial 
peptides in the fat body (a functional equivalent of 
the mammalian liver) and their rapid release into the 
haemolymph is important and the best characterised aspect 
of the insect immune response. Using in situ hybridisation, 
it has been shown that an infectious environment could 
increase the expression of lucifensin in the fat body of 
L. sericata larvae[2]. Lucifensin should be secreted solely 
from this tissue into the haemolymph (similar to other 
insect defensins) and not into excretion/secretion products. 
Injuring sterile maggots with a sterile needle increased 
fourfold the antibacterial activity of haemolymph within 24 h. 
When infected needle was used the antibacterial activity of 
haemolymph increased sixteenfold[6].
   The aim of this study was to investigate the antibacterial 
properties of haemolymph extracted from the larvae after 
septic injury.  
2. Materials and methods
2.1. Rearing of L. sericata larvae
   Colonies of the green bottle fly (L. sericata) were 
maintained at the Institute of Zoology, Slovak Academy of 
Sciences under constant conditions. Imagos were exposed 
to 12 h light/dark photocycles at (25依1) °C and a relative 
humidity of 40-50%. Larvae were fed on ground beef liver 
mixed with bran. 
2.2. Preparation of whole body larval extracts
   The whole body extract from 4-day old larvae in the 
middle of third instars (n=300) was prepared as previously 
described with some modifications[1]. Briefly, larvae 
collected from beef liver, were washed and homogenised 
in grinding mortar using a methanolic extraction buffer 
(methanol/water/acetic acid: 90/9/1). The larval extract was 
vortexed and centrifugated at 10 700 r/min for 30 min at 4 °C 
to remove particular material. The supernatant was collected 
and lyophilized, and the obtained pellet was dissolved in 1 mL 
of ultrapure water. 
2.3. Purification and identification of larval antibacterial 
lucifensin
   Whole body larval extract was used for isolation 
of antibacterial peptide-lucifensin. The purification 
was performed as previously described with some 
modifications[1]. Briefly, extract was loaded onto HiTrap 
CM Sepharose HP column (GE Healthcare, UK) and 
eluted fractions with antibacterial activity were pooled 
and concentrated. This material was submitted to 
fractionation under reverse phase-high performance liquid 
chromatography (RP-HPLC) with a C18 column (250 mm伊
4.6 mm; 5 µm) (Grace, IL USA) at a flow rate 0.3 mL/min by 
using a gradient from 0 to 90% (v/v) acetonitrile [containing 
0.1% (v/v) trifluoroacetic acid], during 70 min, after initial 
5 min at 0% acetonitrile. After lyophilisation, the fractions 
were dissolved in 100 µL of ultrapure water and tested for 
antibacterial activity.
   Mass spectra of antibacterial fraction were acquired in 
positive ion mode using electrospray ionization on a Apex-
Qe Ultra Fourier transform mass spectrometry instrument 
equipped with a 9.4 T superconducting magnet (Bruker 
Daltonics, Billerica, MA, USA).
2.4. Immune-challenge of L. sericata maggots
   Second instar larvae of L. sericata were punctuated 
dorsolaterally with a needle that was contaminated with 
an lipopolysaccharide (LPS) solution (10 mg/mL, crude 
preparation of Escherichia coli endotoxin 0111: B4, Cat. No.: 
L2630, Sigma, Taufkirchen, Germany) and subsequently, 24 h 
post immune-challenge animals were used for collection of 
haemolymph.
2.5. Collection of haemolymph
   Approximately 50 pieces of feeding larvae or larvae after 24 h 
post immune-challenge were removed from liver, thoroughly 
washed, then placed into a 50 mL Erlenmeyer flask and cut by 
scissors into multiple pieces and kept 1 h at 4 °C. The released 
liquid was decanted and centrifuged at 11 000 r/min for 5 min 
at 4 °C to remove all the debris before further processing. 
2.6. RP-HPLC of haemolymph extracts
   Haemolymph extracts were fractionated by using the same 
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HPLC specification and conditions as mentioned previously, 
except that 200 µL was injected onto the column. Fractions 
were collected in 5 min intervals, lyophilized and solid 
resuspended in 200 µL of sterile ultrapure water.
2.7. Determination of antibacterial activity
   Radial diffusion assay was used in order to evaluate 
antibacterial effects of haemolymph fractions. Briefly, one 
bacterial colony of Micrococcus luteus in overnight agar plate 
culture was suspended in phosphate buffer saline and the 
turbidity of suspension was adjusted to 108 CFU/mL. One-
hundred microlitre aliquot of suspension was inoculated to 
10 mL of melted Luria-Bertani broth containing 0.7% (w/v) 
agar pre-heated at 48 °C and poured into 90 mm Petri dishes. 
After solidification, 5 mm-diameter wells were punched 
into Luria-Bertani agar and 5 µL of the sample was added 
to each well. Antibacterial activity of examined samples 
was compared on the basis of radius of clear inhibition zone 
around well after 18-24 h incubation at 37 °C. 
3. Results
3.1. Isolation and identification of lucifensin from larval 
extract
   The whole larval body extract showed antibacterial activity 
against model bacterium Micrococcus luteus. The fraction 
with antibacterial activity after purification on a C18 RP-
HPLC column (Figure 1) was subjected to mass spectrometry 
analysis. High resolution mass revealed that the most 
intensive signal was observed at m/z 4 114.8951 Da which 
corresponded to a recently published oxidized form of 
lucifensin (theoretical mass [M+H+]=4 114.8932)[1]. 
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Figure 1. RP-HPLC of fraction eluted from CM Sepharose column and 
exhibiting antibacterial activity. 
Peak at shown retention time (44.5 min) corresponds to the lucifensin as 
confirmed by MS chromatogram drawn at 280 nm.
3.2. Effect of immune-challenge on lucifensin expression and 
secretion into larval haemolymph
   Maggots in the second instars were punctuated 
dorsolaterally with a needle that was contaminated 
with an LPS solution and after 24 h used for collection 
of haemolymph. The final larval haemolymph was used 
for examination the antibacterial activity. Haemolymph 
extracted from non-challenged larvae has been used 
as a control. Both haemolymph extracts were tested for 
antibacterial activity. We observed significant increase 
in the antibacterial activity of the haemolymph following 
the septic injury (data not shown). After this primary test, 
extracts have been subjected to fractionation using the 
same protocol as for the purification of lucifensin. The only 
fraction exhibiting antibacterial activity was collected at 
the retention time where lucifensin is supposed to be eluted 
(Figure 2). We could therefore conclude that increased 
antibacterial activity of haemolymph in LPS-stimulated 
larvae was solely caused by the increased expression of 
lucifensin.
Figure 2. Antibacterial activity of haemolymph fractions from LPS-
stimulated and normal larvae.
Injuring larvae with LPS caused significant increase in antibacterial activity 
of lucifensin containing haemolymph fraction (A) in comparision to the non-
challenged one (B).
4. Discussion
   In this study, peptide lucifensin with molecular mass 
of 4 113.89 Da was isolated and identified as an exclusive 
antibacterial compound in maggots. Lucifensin belongs to 
the insect defensins, small (~5 kDa), basic, cysteine-rich 
antibacterial peptides with efficacy against Gram-positive 
bacteria[7,8]. Most defensins almost immediately kill bacteria 
by permeabilization of their cytoplasmic membrane[9-11]. 
Insect defensins are either inducibly expressed in the fat 
body during systemic immune responses or alternatively 
might be constitutively expressed in tissues which are in 
continuous contact with potentially infectious environments, 
like salivary glands of L. sericata. Lucifensin expression 
has been detected in the salivary glands of all larval 
stages and occasionally in a few cells of the fat body and 
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in the grease coupler of salivary glands. Certain infectious 
environment could increase lucifensin expression in the 
fat body and the secretion into haemolymph[2]. Immune-
challenging the larvae with LPS caused the same systemic 
response. Lucifensin production has been upregulated and 
haemolymph of such animal show increased antibacterial 
activity. Using liquid chromatography techniques we 
confirmed that the increased antibacterial activity 
corresponded solely with lucifensin fraction. 
   In conclusion, our results suggest, that beside the 
previously demonstrated role of lucifensin in the maggot 
debridement therapy, lucifensin is simultaneously important 
as a part of the systematic immune response.
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Comments 
Background
   The study of antimicrobial peptides is an important 
research field, and in the present work the authors focused 
on the determination of the antimicrobial activity of a 
member of these antimicrobial peptides, such as the 
lucifensina in maggot before and after a LPS challenge. 
Indeed found that these peptides are inducible.
Research frontiers
   In this paper, the authors provide with the frontiers of 
knowledge to establish that the antimicrobial peptide 
lucifensina which was not found in the digestive tract of the 
larvae of the fly L. sericata as was believed, was considered 
as a component of the products of excretion/secretion.
Related reports
   There are numerous publications on insects antimicrobial 
peptides as components of the innate immune system and its 
antibacterial activity.
Innovations and breakthroughs
   This study establishes the antimicrobial property of 
peptide lucifensin, which was not found in the digestive 
tract of the larvae of the fly L. sericata as was believed.
Peer review
   This is a valuable research work in which authors have 
demonstrated that the antimicrobial peptide lucifensin was 
not found in the digestive tract of the larvae of the fly L. 
sericata as was believed and that lucifesin was isolated to 
the haemolymph and found higher antibacterial activity of 
such haemolymph in comparison to non-stimulated larvae.
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